Loading…
← CockpitCompetitor Analysis › DOCS.L Dr. Martens PlcOpen in the cockpit ↗

Dr. Martens PlcDOCS.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Consumer Discretionary›Apparel/Footwear
Momentum laggard 6
Mkt cap
$701M
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$2.10M
20-day average traded
Fwd P/E
14.3×
forward earnings
ROIC−WACC
+0.6 pp
WACC 7.6%
Hurdle
+0 pp
Req g minus delivered
Next earnings
197 days
3 Jun 2027
Close · GBP£56.10
1D+1.6%
1W-11.5%
1M-16.5%
3M-28.9%
6M-19.4%
YTD-26.8%
1Y-32.3%
ATR %6.4%
52w lowhigh37.7% off high

What Dr. Martens does

Employees: 2,377

Dr. Martens at a glance

Size Dr. Martens (DOCS.L) is a United Kingdom Consumer Discretionary company (Apparel/Footwear) with a market value of $701M, the 252nd largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £56.10 on 18 Nov 2026.

Performance Over six months the shares fell 19.4%, against -10.2% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 6.6% over the last twelve months (peer median +7.3%); the operating margin is 9.5% (peer median 7.7%).

Valuation It trades at 14.3× forward earnings against a peer median of 17.0× (7th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points above its cost of capital (7.6% WACC).

Next results Next results expected around 3 Jun 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 91DOCS.L 80
Six months, rebased to 100: Dr. Martens against the median of its 20 peers (local-currency closes).

Dr. Martens financials

Reported figures in GBP; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£733M£766M£788M£877M£1.00B
Revenue growth—-3%-10%-12%—
Gross profit£418M£439M£439M£503M£564M
EBITDA£138M£142M£133M£199M£245M
Net income£27.8M£23.8M£4.50M£69.2M£129M
Free cash flow£92.3M£116M£160M£133M£32.1M
Capital expenditure£13.2M£11.9M£18.7M£28.4M£51.4M
Total debtn/a£391M£402M£469M£446M

Quarterly statements and history in the cockpit →

Dr. Martens competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%3612RELAXO6015668016002154LOGI-B002029CAMPUSGOOS6035117839PDSL603196300981603608GOKEX603558WEYSDOCS.L6-month return →1-month return →
Up and to the right = strong over both horizons. Dr. Martens is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×40×3612RELAXO6015668016002154LOGI-B002029CAMPUS7839603877PDSLBATAINDIA603196GOKEXDOCS.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dr. Martens is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3612RELAXO6015668016002154LOGI-B002029CAMPUSGOOS6035117839603877PDSLBATAINDIA603196300981603608WEYSDOCS.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dr. Martens is the large dot.

Dr. Martens competitors and peer comparison

How Dr. Martens compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dr. Martens against its 20 peers (data as of 18 Nov 2026)
MeasureDOCS.LPeer medianRank in peer set
1-month return-16.5%-4.0%5th lowest of 21
6-month return-19.4%-10.2%6th lowest of 21
Distance from 52-week high-37.7%-34.2%10th lowest of 21
Revenue growth (TTM)-6.6%+7.3%lowest of 21
Operating margin9.5%7.7%8th highest of 21
Forward P/E14.3×17.0×7th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.0%-0.4%10th least demanding of 19
Growth delivered (Del g)-0.2%+6.3%7th lowest of 19
Hurdle (Req g minus delivered)+0.1 pp-4.6 pp7th most demanding of 19
ROIC minus cost of capital+0.6 pp+0.3 pp10th highest of 21
EV / EBITDA6.1×8.8×2nd cheapest of 10
Net debt / EBITDA2.2×1.2×3rd most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dr. Martens DOCS.LUnited Kingdom$701M-19%-7%10%14.3×0.0%-0.2%
World 3612.TJapan$700M-3%+15%6%8.4×-5.1%+9.5%
Relaxo Footwears RELAXO.NSIndia$709M-8%+7%8%31.5×31.6%+2.8%
JOEONE 601566.SSChina$712M-26%+1%6%38.4×-9.2%+2.1%
Onward 8016.TJapan$663M+5%+7%5%9.4×1.8%+6.1%
Bxn 002154.SZChina$743M-25%+6%7%11.4×-10.2%+6.5%
Logistea LOGI-B.STSweden$745M+1%+18%83%12.3×14.7%+40.4%
Fujian Septwolves Industry 002029.SZChina$639M-39%+1%-3%14.8×-4.6%-2.0%
Campus Activewear CAMPUS.NSIndia$637M-16%+14%11%29.4×34.0%+20.1%
Canada Goose GOOS.TOCanada$773M-12%+12%10%13.0×6.1%+11.0%
AIMER 603511.SSChina$635M-28%-2%4%n/a-8.1%-1.6%
Shoei Co. Ltd. (7839) 7839.TJapan$775M+32%+8%29%16.4×-8.2%+7.9%
Ningbo Peacebird Fashion 603877.SSChina$796M-18%-2%4%24.5×-13.9%-7.5%
PDS PDSL.NSIndia$614M+38%+11%2%43.6×12.3%+16.1%
Bata India BATAINDIA.NSIndia$859M-10%+5%9%38.6×28.6%+15.5%
Shanghai Puyuan Chemical Materials 603196.SSChina$859M-51%+78%12%17.7×14.3%-0.2%
Zhonghong Pulin Medical Products 300981.SZChina$875M-11%+11%9%n/a-4.3%-13.1%
Topscore Fashion 603608.SSChina$878M+1%+8%3%n/a38.4%-9.4%
Gokaldas Exports GOKEX.NSIndia$559M+3%+9%5%21.9×n/an/a
ZheJiang Jasan 603558.SSChina$540M-15%+6%17%10.1×n/an/a
Weyco WEYSUnited States$530M+58%+2%17%n/a-2.6%+7.2%

Questions

Which companies are Dr. Martens's closest peers?
The cockpit's peer set: World (3612.T), Relaxo Footwears (RELAXO.NS), JOEONE (601566.SS), Onward (8016.T), Bxn (002154.SZ), Logistea (LOGI-B.ST), Fujian Septwolves Industry (002029.SZ), Campus Activewear (CAMPUS.NS).
Is Dr. Martens expensive compared with its peers?
On forward p/e it trades at 14.3× against a peer median of 17.0×, 7th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Dr. Martens stock performed?
Over six months to 18 Nov 2026 the shares returned -19.4% against -10.2% for the median peer; over one year -32.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.